Re-exam sought of patents involved in new stem cell litigation
from :
ThermoGenesis reported on March 1, 2005 that the patent office had reviewed and rejected the claims of a PharmaStem patent related to collection and preservation of umbilical cord and placental blood stem cells and the use of the cells to treat disease.
That patent was a basis for a lawsuit PharmaStem pursued against several defendants, including the ViaCord unit of ViaCell Inc. (Nasdaq: VIAC) and Cryo-Cell International Inc. (OTCBB: CCEL). A jury in October 2003 found that the patents were valid and enforceable, but a federal judge in Delaware overturned the ruling in December 2004. PharmaStem filed suit in January, 2005 against some of the same defendants on the basis of two other patents -- the patents that ThermoGenesis now has asked regulators to review.
ThermoGenesis reported on March 1, 2005 that the patent office had reviewed and rejected the claims of a PharmaStem patent related to collection and preservation of umbilical cord and placental blood stem cells and the use of the cells to treat disease.
That patent was a basis for a lawsuit PharmaStem pursued against several defendants, including the ViaCord unit of ViaCell Inc. (Nasdaq: VIAC) and Cryo-Cell International Inc. (OTCBB: CCEL). A jury in October 2003 found that the patents were valid and enforceable, but a federal judge in Delaware overturned the ruling in December 2004. PharmaStem filed suit in January, 2005 against some of the same defendants on the basis of two other patents -- the patents that ThermoGenesis now has asked regulators to review.
posted by Lawrence B. Ebert at 3:24 PM
0 Comments:
Post a Comment
<< Home